A Brave New Paradigm for M&A - Serial Acquisition Options

Authored by Han Smit, Professor of Corporate Finance, Erasmus University, Netherlands
Authored by Thras Moraitis, FORMER Executive General Manager Group Strategy and Corporate Affairs, Xstrata plc, London, United Kingdom

A serial M&A strategy is a powerful strategic option for businesses wishing to grow in a specific market or for a private equity firm pursuing a buy-and-build strategy. Thras Moraitis, Executive General Manager Group Strategy and Corporate Affairs at Xstrata plc, and Han Smit, Professor of Corporate Finance at Erasmus University, reveal how some fresh thinking is needed to deliver a successful acquisition strategy.

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

IPEM Allocation and Fundraising Trend Report 2027

The private markets industry is entering a new investment cycle, with LPs increasingly focused on diversification, alpha generation and demonstrable value creation, as return expectations come under pressure. This repor...


Click here to download this insight

HR Shared Services Trends Report 2026

The world of HR is evolving rapidly, as organisations look to improve efficiency, embrace AI and enhance the employee experience. This report by LACE Partners looks into how organisations can balance artificial intel...


Click here to download this insight

BLOG | Human Capital at the Crossroad

Artificial intelligence, geopolitical instability and sustained economic uncertainty are reshaping the human capital agenda and placing new demands on Boards. Workforce models, skills requirements, talent strategies ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 199




NatWest Group London Stock Exchange Group Global Payments Drax Group plc Hitachi Solutions E.ON UK LACE Partners Rolls-Royce Legal & General AlixPartners NATS Lightsource bp Stream Mayborn Group British Land GlaxoSmithKline plc